Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder
JACC: Clinical Electrophysiology · 2026-06 · 12 (6) · 1331-1341
DOI: 10.1016/j.jacep.2026.01.021 ↗Kurz gefasst
Klinische Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2026-06. Verfasst von Devi Nair und 14 weiteren Autor:innen. Beteiligte Einrichtung: St. Bernard's Heart and Vascular Center, Jonesboro, Arkansas, USA. Electronic address: drdevignair@gmail.com. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Left Atrial Appendage Closure, Septal Occluder Device. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott Pharmaceuticals, Abbott Laboratories.
Abstract (Originalsprache)
BACKGROUND: Percutaneous left atrial appendage occlusion (LAAO) is an alternative stroke prevention strategy in atrial fibrillation patients deemed unsuitable to tolerate long-term oral anticoagulation. Although current LAAO devices have been shown to provide stroke protection, they have been associated with peridevice leak and pericardial effusion. The VERITAS study evaluates the safety and effectiveness of Abbott's next-generation dual-seal LAAO device. OBJECTIVES: The purpose of this study was to assess the VERITAS primary endpoints and key clinical outcomes through 45 days. METHODS: In this prospective, global, multicenter, single-arm study, atrial fibrillation patients with CHA2DS2-VASc ≥2 for men and ≥3 for women underwent LAAO with the next-generation dual-sealing device (Amulet 360). The primary safety endpoint included key adverse events through 7 days postprocedure or hospital discharge, whichever was later. The primary effectiveness endpoint was LAAO (leak ≤5 mm) by 45-day transesophageal echocardiography, assessed by an independent core laboratory. RESULTS: Across 34 global sites, 400 patients (age 73.8 ± 7.4 years, 62% men, CHA2DS2-VASc 4.1 ± 1.4, and HAS-BLED 3.1 ± 1.0) were enrolled and underwent an implant attempt. LAAO implant success was 99.8% (399 of 400). The incidence for the primary safety endpoint was 0.0% (0 of 400). All (100%) patients assessed with echocardiography met the primary effectiveness endpoint. At 45 days, complete LAAO (0 mm leak) was observed in 93.9% of patients. Two (0.5%) patients required percutaneous draining for pericardial effusions and device-related thrombus was observed in 2.4% of patients. CONCLUSIONS: The VERITAS study demonstrates high implant success of the next-generation dual-seal LAAO device, and a favorable short-term safety and sealing profile. (Abbott Medical-VERITAS Study; NCT06707688).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- St. Bernard's Heart and Vascular Center, Jonesboro, Arkansas, USA. Electronic address: drdevignair@gmail.com.
- Hospital Clinic de Barcelona, lnstitut Clinic Cardiovascular, Barcelona, Spain.
- Vanderbilt Heart Institute, Nashville, Tennessee, USA.
- Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, USA.
- Aarhus University Hospital, Aarhus N, Denmark.
- Texas Cardiac Arrythmia, Austin, Texas, USA.
Förderung
- Abbott Pharmaceuticals
- Abbott Laboratories
Zitieren
APA
Nair, D., Freixa, X., Ellis, C. R., Lakkireddy, D., Nielsen-Kudsk, J. E., Horton, R., Reddy, V. Y., Makkar, A., Ibrahim, R., Agarwal, H., de Backer, O., Sabir, S., Weiler, C., Alkhouli, M., & VERITAS Investigators (2026). Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder. JACC: Clinical Electrophysiology, 12(6), 1331-1341. https://doi.org/10.1016/j.jacep.2026.01.021
Vancouver
Nair D, Freixa X, Ellis CR, Lakkireddy D, Nielsen-Kudsk JE, Horton R, et al. Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder. JACC: Clinical Electrophysiology. 2026;12(6):1331-1341. doi:10.1016/j.jacep.2026.01.021
BibTeX
@article{Nair2026,
author = {Nair, Devi and Freixa, Xavier and Ellis, Christopher R and Lakkireddy, Dhanunjaya and Nielsen-Kudsk, Jens Erik and Horton, Rodney and Reddy, Vivek Y and Makkar, Akash and Ibrahim, Reda and Agarwal, Himanshu and de Backer, Ole and Sabir, Sajjad and Weiler, Courtney and Alkhouli, Mohamad and VERITAS Investigators, VERITAS Investigators},
title = {Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder},
journal = {JACC: Clinical Electrophysiology},
year = {2026},
volume = {12},
number = {6},
pages = {1331--1341},
doi = {10.1016/j.jacep.2026.01.021}
}
EUVIMED